Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Figure 1 Flow chart of patient selection process. This flow chart summarizes patient identification for eligibility and inclusion/exclusion criteria.

Figure 2 Sustained virologic response rates among patients with various clinical and demographic characteristics. SVR: Sustained viral response.

Figure 3 Area under a receiver operating characteristic curve for hepatitis C RNA viral load was 0. 734 (P < 0.001, 95%CI: 0.66-0.82).